Anyone buying the core component – the saccadic fixator – off the shelf can have it for $3,000, optional wall mounting hardware costs another $500.
Binovi is operating in two verticals, medical and sports. The literature is now a lot more comprehensive about the competition the company faces in what appears to be a burgeoning, but crowded marketplace. Small cap isn’t usually the province of management consultants, so it’s evident that someone is taking the need to shore up operations very seriously. Central to the investor-facing side of the story now is the company’s use of management consulting firm Arcan to sort its operations out. Since re-branding as Binovi, this company has done a major overhaul of the template upon which it builds its quarterly filings. The author had put it together as though they didn’t expect anyone to ever read it, betraying the fact that the company didn’t care about the fundamentals of the business enough to properly explain them to investors. The problem was one of shoddy workmanship. It wasn’t that the literature was too promotional – that’s the sort of thing one expects out of venture-stage tech. They featured a market outlook statement that leaned heavily on the potential in the market for these devices, without mentioning the competition in that market at all. The tone and construction of the November quarterlies that preceded our last encounter with this issue ran pretty fast and loose. The latest news is about its acquisition of a vision screening tech for school children called VERA for another 13 million shares. It has since issued a round of $0.1275 stock to raise $2 million, and done a 1.22 million shares-for-debt deal, to round its total out to 113 million shares or so. numbered company that owned something called VIMA Rev Strobe Lenses (subject to royalties on the gross sales of the product that survive the transaction), and an Alberta numbered company that owned a domain name, for an aggregate total of 20.1 million shares.įollowing capital raises and the exercise of warrants and options, Binovi finished August 2020 with 81.7 million shares outstanding, and five thousand dollars in cash. Since then, the company has made further all-stock acquisitions of a B.C.
#NEUROTRACKER FAST COMPANY TINY SOFTWARE#
On the last episode, we pointed out that 9.1 million of the 50.7 million outstanding shares at the time were issued to buy software as a service company ConnectMe at a nominal value of $0.45, but no cash cost to their owners. The volume had been fairly quiet since the spring, but has picked back up as we moved into December, Binovi having traded 23.5 million shares over the three sessions to gain $0.025 (+11%) and close at $0.225 on the TSX.V Wednesday, so it’s time for a look at what they’ve been up to. At the time, the company was selling a reflex and eyesight sharpening system called Binovi, but still calling itself “Eyecarrot.” Binovi Technologies (TSXV:VISN), last appeared in the Market Movers column this past May, when it had created some fresh volume behind the appointment of controversial former Aurora Cannabis CEO Terry Booth as the company’s Executive Chairman.
0 kommentar(er)
